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ABSTRACT 
BACKGROUND:  Preclinical work suggests Src proteins have a role in the 
development of resistance to vascular endothelial growth factor (VEGF) targeted 
therapy in metastatic clear cell renal cancer (mRCC) 
OBJECTIVE: To test the hypothesis that the addition of a Src tyrosine kinase 
inhibitor (TKI) saracatinib to VEGF targeted therapy (cediranib) improves outcomes 
in VEGF resistant mRCC.  
DESIGN, SETTING, AND PARTICIPANTS: Patients with disease progression after 
≥1 VEGF targeted therapy were eligible to participate in this investigator-led, double-
blind, randomised (1:1) phase II study. Between 2010 and 2012, 138 patients were 
randomised across 16 UK sites. Archived tissue was used for biomarker analysis 
(SRC, FAK, VHL, PTB1b and HIF2α: n=86). 
INTERVENTION: Patients received cediranib 30mg  once daily (OD) and saracatinib 
175mg OD (CS) (n=69) or cediranib 45mg OD and placebo OD (C) (n=69). 
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary 
endpoint was progression free survival (PFS) by RECIST v1.1 (Response Evaluation 
Criteria in Solid Tumours v1.1). Secondary endpoints included tolerability, response 
rates, overall survival (OS). Biomarker analysis was performed.  
RESULTS AND LIMITATIONS: The characteristics of the two groups were well 
balanced. Partial responses were seen in 13.0% for C and 14.5% for CS respectively 
(P>0.05). There was no significant difference in PFS [5.4 months (3.6-7.3 months) for 
C and 3.9 (2.4-5.3 months) for CS; Hazard Ratio (HR) 1.18 (0.94-1.48)], or overall 
survival (OS) [14.2 months (11.2-16.8 months) for C and 10.0 (6.7-13.2 months) for 
CS; [HR 1.28 (1.00-1.63)]. There was no significant difference in the frequency of key 
adverse events, dose reductions or drug discontinuations.  None of the biomarkers 
were prognostic for PFS or OS.  Focal adhesion kinase (FAK) overexpression 
correlated with an OS benefit [HR 2.29 (1.09-4.82)], but not PFS, for CS. 
CONCLUSIONS: Saracatinib did not increase the efficacy of a VEGF targeted 
therapy (cediranib) in this setting. Biomarker analysis did not identify consistent 
predictive biomarkers.  
   
ClinicalTrials.gov number NCT00942877. 
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INTRODUCTION 
Second line vascular endothelial growth factor (VEGF) targeted therapy is less active 
than first line VEGF targeted therapy in metastatic clear cell renal cancer (mRCC) [1]. 
There appears to be significant cross resistance between these drugs rendering 
subsequent therapy less active than the previous treatment. This has been described 
as a ‘law of diminishing returns’ [1, 2].  
 
The mechanism of resistance to VEGF targeted therapy in mRCC is unknown.  
Alternative pathways such as SRC may play a role in progression of disease [3-5]. 
Preclinical data shows Src may be involved in stability of the von Hippel-Lindau 
(VHL) gene and overexpression is associated with poor outcomes in RCC.  Further 
data show that the combination of VEGF targeted therapy and the Src inhibitor, 
saracatinib, are synergistic in renal cancer cell lines [4]. Therefore, saracatinib may 
enhance the activity of VEGF targeted therapy.  Preclinical work also points towards 
the potential for a personalised approach with this combination. Overexpression of 
protein tyrosine phosphatase 1b (PTB1b) and focal adhesion kinase (FAK) appeared 
to be relevant in determining outcome [4].  
 
Cediranib is a potent VEGF tyrosine kinase inhibitor (TKI) with significant activity in 
renal cancer patients who have not previously received VEGF targeted therapy, with 
comparable progression-free survival (PFS) results to those seen with sunitinib, 
pazopanib and axitinib  [1, 6-8]. It was not further developed in mRCC due to 
established alternatives in this arena. Cediranib was used as it was the only VEGF 
agent with phase I data in combination with saracatinib.  Phase I data showed that 
cediranib monotherapy was well tolerated and efficacious at a dose of 45mg once 
daily (OD) [6, 9].  However, a dose reduction for cediranib to 30mg OD was required 
when used in combination with saracatanib 175mg OD due to a dose-limiting toxicity 
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(hypertension) [10].  The combination was well tolerated with manageable and 
largely non-overlapping side effect profiles [10].  
 
Preclinical animal model work suggests PTB1b and FAK may be relevant in 
predicting response to Src inhibition [4].  It is conceivable that the SRC inhibition is 
only active in biomarker driven subsets of patients. For this reason a number of 
relevant biomarkers (SRC, FAK, VHL and hypoxia-inducible factor 2α (HIF2α)) were 
measured from archived tissue.  
 
The aim of this study was to determine if the addition of a SRC inhibitor (saracatinib) 
to a VEGF TKI (cediranib) led to an improved PFS compared to VEGF inhibition 
alone in mRCC patients who have already failed VEGF-targeted therapy.  We also 
explored the predictive nature of PTB1b, FAK and other biomarkers in this setting.   
 
 
 
MATERIALS AND METHODS 
Patient population and study drug 
Inclusion criteria included histopathologically-confirmed, measurable (by Response 
Evaluation Criteria in Solid Tumours (RECIST) v1.1) metastatic clear cell RCC. 
Patients were required to have progressive disease on VEGF targeted therapy and 
be naïve to mammalian Target of Rapamycin (mTOR) inhibitors.  Prior immune 
therapy and >1 line of VEGF targeted therapy was permitted.  Adequate end organ 
function was required.   Patients with Eastern Co-operative Oncology Group (ECOG) 
performance status (PS) of 0-2 were permitted. Exclusion criteria focused on the 
standard exclusion criteria for VEGF targeted therapy studies, such as untreated 
brain metastases, uncontrolled hypertension/cardiac disease, bleeding, excessive 
proteinurea and concurrent alternative malignancies.  
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Patients were randomised (1:1) in a double blinded fashion. They received either 
cediranib 30mg PO OD + saracatinib 175mg PO OD  or  cediranib 45mg PO OD + 
placebo PO OD. Doses were based on single agent and combinations data from 
phase I-II studies [6, 10].  Dose interruptions (28 days) or reductions were permitted 
[(i) cediranib 20mg and saracatinib 175mg: (ii) cediranib 15mg and saracatinib 
125mg].     
 
Endpoints and assessment.  
The primary outcome was to investigate the progression free survival (PFS) of the 
combination of cediranib and saracatinib compared to cediranib and placebo. 
Secondary objectives included response rates (RR), overall survival (OS), adverse 
events (AEs) and specific biomarker analysis from archived tissue [SRC, VHL, FAK, 
HIF2α, PTB1b].  
 
 Patients were randomised to receive study drug until progression of disease, death, 
excess toxicity or discontinuation for another reason. Radiological assessment 
(RECIST v1.1) occurred eight weekly until progression. No central radiological review 
occurred. Clinical assessment occurred on a four weekly basis. AEs were graded 
according to the National Cancer Institute’s Common Terminology Criteria for AEs, 
version 3.0 (CTCAE v3.0). Stratification factors included performance status, duration 
on first line VEGF targeted therapy (<6 months) and Memorial Sloan Kettering 
Cancer Centre (MSKCC) prognostic score [11].  
 
Statistical analysis and ethical considerations 
The study was designed to detect a 50% improvement (from four months to six 
months) in median PFS by adding saracatinib to cediranib with 90% power at the 
20% 1-sided level of statistical significance. The efficacy was estimated from 
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previous studies in this area [1, 12].  The primary analysis required 110 PFS events. 
Approximately 130 patients (65 per arm) were required to achieve this. All analyses 
were conducted on an intention-to-treat basis. Progression-free survival was 
compared between the study arms in the context of a Cox model incorporating the 
baseline stratification factors.  The study had appropriate regulatory and ethical 
approval: ClinicalTrials.gov number NCT00942877.  
 
Biomarker analysis 
A tissue microarray (TMA) was constructed from biopsy tissue samples from 78 
patients. 4µm thick sections were deparaffinised and rehydrated using xylene and 
alcohol, and incubated with 0.3% hydrogen peroxide to block endogenous peroxidise 
activity. Heat-mediated antigen retrieval was performed in citrate buffer (pH 6.0). The 
following antibodies were used to assess protein expression: VHL (1:200; BD 
Pharmingen), FAK (1:100; Cell Signalling), SRC (1:200; Cell Signalling), PTB1b 
(1:2500; Abcam), HIF2α (1:3000, Novus Biologicals). The TMA was then processed 
using either EnVision Kits (DAKO) or VECTASTAIN ABC Kit (Vector Labs) according 
to manufacturer’s instructions. A single pathologist scored the immunohistochemical 
(IHC) expression. The immunohistochemical scoring was performed independently 
and blinded to patient outcome data using the weighted histoscore method. 
Expression was scored by staining intensity (0, negative; 1+, weakly positive; 2+, 
moderately positive; 3+, strongly positive), then multiplying with the percentage of 
tumour cells seen within each section. 
 
 
RESULTS 
Patient population 
Between 2010 and 2012, 138 patients were randomised into this study across 16 
sites in the UK. Median age for the population was 60 years (interquartile range 54-
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67 years). Eighty-two percent of patients previously received sunitinib. Overall 96% 
received only one previous VEGF targeted therapy, the remainder received two 
previous lines of VEGF therapy. Twenty percent of patients had previously received 
immune therapy as initial treatment for metastatic disease prior to subsequent VEGF 
targeted therapy. Overall 15%, 70%, 15% had MSKCC good, intermediate or poor 
risk disease respectively at the time of randomisation. The characteristics of the two 
groups (n=69 for each) were well balanced (Table 1).  A consolidated standards of 
reporting trials (CONSORT) diagram summarises the trial in Figure 1.  Sixty-six 
patients (32%) failed during screening.  There were no specific exclusion criteria 
unique to this study. It was felt that the screen failure rate reflects the advanced 
nature of the cancer.  The presence of brain metastases, worsening performance 
status and inadequate organ function were common reasons for exclusion. 
 
Efficacy analysis 
The median progression free and overall survival for the whole group was 4.1 months 
(95% confidence interval (CI): 3.1-5.1 months) and 12.0 months (95% CI: 8.5-15.6 
months) respectively. Partial responses were seen in 13.0% for cediranib and 14.5% 
for cediranib and saracatinib respectively (P>0.05).  Progression of disease as best 
response occurred 29% for cediranib and 20% for cediranib/saracatinib (P>0.05). 
There was no significant difference in PFS [5.4 months (3.6-7.3 months) for cediranib 
and 3.9 (2.4-5.3 months) for cediranib/saracatinib: Hazard Ratio (HR) 1.18 (0.94-
1.48) P>0.05] or OS [14.2months (11.2-16.8 months) for cediranib and 10.0 (6.72-
13.2 months) for cediranib/saracatinib: HR 1.28 (1.00-1.63) P>0.05] for the two 
cohorts (Fig. 2 and Fig. 3). Forest plot analysis showed no consistent subsets that 
benefited from the combination with the exception of patients with PS 0 (compared to 
1 or more) (Fig. 4). Due to the small numbers in this group the results may be 
artefact. Subsequent targeted therapies (VEGF or mTOR) were given in 25 (36%) 
cediranib and 33 (47%) cediranib/saracatinib patients.  
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Adverse events 
There were no significant differences in the frequency of key AEs (Table 2). Lethargy 
and diarrhoea were the most common AEs in both arms (>75% for all grades in both 
arms and >10% grade 3/4 for both arms).  Dose reductions and discontinuation due 
to AEs with cediranib and cediranib/saracatinib occurred in 13% and 8% vs. 19% and 
18% respectively (P>0.05). The commonest reason for dose reduction with the 
combination was diarrhoea (n=4).  
 
Biomarker analysis and exploratory endpoints 
Archived tissue was available from 86 (62%) patients. High levels (IHC 2+/3+) of 
FAK, SRC, PTB1b and HIF2α were present in 48%, 31%, 38% and 15% 
respectively.  High levels of VHL were seen in 65% of patients. None of these 
biomarkers were prognostic in terms of PFS or OS (Table 3). FAK expression was 
predictive of OS [HR: 2.29 (95% CI: 1.09-4.82) P<0.05] but not PFS [HR: 0.85 (95% 
CI: 0.58-2.40) P>0.05] (Table 3). 
 
 
DISCUSSION 
The aim of this study was to determine if the addition of a SRC inhibitor (saracatinib) 
to a VEGF TKI (cediranib) overcame VEGF resistance in patients who progressed 
after prior VEGF targeted therapy.  Preclinical work suggests the combination of 
cediranib and saracatinib are more active than cediranib alone in mRCC [4]. Our 
clinical results show this was not the case in VEGF resistant mRCC. Therefore 
further evaluation of the combination in this setting is not recommended.  
 
The combination was tolerable and comparable in the two study arms. Adverse 
events were dominated by the toxicity seen with cediranib, with diarrhoea, lethargy, 
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nausea/vomiting and hand/foot syndrome being most prominent. However 18% of 
patients discontinued the combination due to toxicity compared to 8% with cediranib 
alone. This figure (18%) is numerically higher than those seen with axitinib or 
everolimus in the pivotal trials and may have been relevant in the efficacy results [1, 
12].  While indirect comparisons across trials are not valid, the discontinuation rate in 
this study is high. There are a number of factors which may have contributed to this, 
ranging from co-morbidities to treatment related toxicity. It underlines the importance 
of management of toxicity. 
 
Patients’ characteristics in the two groups were balanced and in line with previous 
studies [1, 12].  Most patients had MSKCC intermediate risk disease having failed 
one line of therapy (96%) (pazopanib or sunitinib in >95%). Forest plot analysis 
showed the only subgroup of patients which appeared to gain advantage with the 
combination were those with PS <1. There is no scientific rationale why this may be 
the case, although previous work with axitinib also suggested PS may be relevant in 
predicting response to targeted therapy [13].  
 
Cediranib was used as it was the only VEGF agent with phase I data in combination 
with saracatinib.  Had the trial been positive, the correct competitor for the 
randomised phase III trial would have been axitinib.  Pharmacokinetic data from the 
phase I saracatinib study suggested 175mg OD is an active dose, while 30mg OD of 
cediranib has activity and was the optimal dose for combinations.  This dose of 
cediranib has resulted in positive studies in other tumours [14, 15]. Overall the doses 
in this study tested the optimal doses of both arms to best interrogate the efficacy of 
the combination. However, in our study, it is possible that cediranib at 45mg in the 
control arm resulted in additional activity compared to 30mg in the combination arm. 
Nevertheless, these effects are likely to be subtle and it is hard to justify taking either 
arm forward at this stage. The relatively high discontinuation rate with the 
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combination (18%) suggests further dose adjustments to improve efficacy are not 
worthwhile.  
 
The activity of single agent cediranib at 45mg (RR=13% PFS 5.4 months 
[investigator assessed]) was in line with other agents tested in VEGF refractory 
disease (axitinib RR=19% PFS 6.5 months [investigator assessed] and sorafenib 
RR=10% PFS 4.5 months [investigator assessed]) [1]. Cediranib is not being further 
investigated in mRCC largely due to the competitive landscape. However it has 
positive results and is being developed in other tumours such as ovarian cancer [14]. 
 
The overall survival of 12 months in our trial is modest, especially as most patients 
were being treated in the second line setting. However, this is within the range of the 
OS seen in other randomised trials in this setting (14.8 months) [16]. Shorter survival 
may in part be due to patient selection and limited access to therapies for RCC in the 
UK, although a significant proportion received further therapy in this study (36-47%).  
Recent advances with immune therapy showed prolonged survival with nivolumab in 
VEGF resistant disease [17]. The median overall survival was over 25 months with 
this agent. This reflects the rapid progress of treatment development in renal cancer.  
 
Preclinical work suggests FAK, which is downstream of SRC, and PTB1b, which is 
linked to tumour growth in breast cancer, may be important in the identification of 
patients who benefit from saracatinib and cediranib combination therapy [4, 18].  Our 
biomarker analysis was unable to confirm this although FAK overexpression 
predicted survival (but not PFS) to the drug combination.  Further exploration of this 
may be warranted in other settings.   It is unclear why FAK was predictive for OS, but 
not PFS.  Given its role in co-ordinating integrin signalling and cell migration, one 
possibility is that FAK inhibition reduces metastatic spread without affecting local 
growth of the tumour [19].  Further evaluation is required.  It is possible that 
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biomarker expression from archived tissue was not representative of biomarker 
expression at the time of randomisation. This questions the validity of this exploratory 
endpoint. Collection of fresh tissue in randomised trails has proved challenging. 
 
While SRC inhibition may be promising theoretically and preclinically, targeting single 
tyrosine kinases in VEGF resistant patients may not be optimal due to the tumour 
heterogeneity seen clinical setting. To support this, similar results were seen with 
dovitinib (a FGF-2 inhibitor) in VEGF refractory disease [20].  Other resistance 
pathways may also be involved (reviewed by [21]) 
  
In addition to the limitations discussed above, the lack of independent radiology 
review to determine PFS is a weakness of this study. Although cediranib is not a 
licensed treatment in renal cell carcinoma, similarities in the mechanism of action 
mean that it is uncertain if a different outcome would have been found if axitinib had 
been used.  Therefore, further evaluation in the VEGF resistant setting is not 
recommended.  However, it remains an open question as to whether the combination 
in a first line setting may be more efficacious by potentially preventing the 
development of VEGF resistance.  Biomarker analysis was carried out on archival 
tissue.  This may have limited the ability to analyse the predictive value of some of 
the biomarkers in the VEGF resistant setting.    
 
CONCLUSIONS 
Together these data suggest that cediranib has activity in this setting, as one might 
expect in view of its mechanism of action. While direct comparisons with other trials 
are not possible, indirectly there is nothing from this study to suggest the single agent 
cediranib would be superior to other agents such as axitinib or everolimus in this 
setting.  The addition of saracatinib to cediranib was relatively well tolerated, but did 
not improve efficacy. This suggests the preclinical hypothesis is flawed rather than an 
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inability to give the drugs together. We were also unable to robustly replicate the 
preclinical biomarker data which pointed towards a personalised approach with these 
drugs. However, further exploration of FAK may be warranted.   
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Table 1: Patients’ characteristics at baseline 
VEGF = vascular endothelial growth factor; MSKCC = Memorial Sloan Kettering 
Cancer Centre; CR = complete response; PR = partial response; SD = stable 
disease; PD = progressive disease. 
 
 
Table 2: Most common adverse events (CTCv3.0)  
 
 
Table 3: Biomarker analysis (prognostic and predictive evaluation) 
*of statistical significance.  PFS = progression free survival; OS = overall survival; CI 
= confidence interval; FAK = focal adhesion kinase; VHL = von Hippel-Lindau; 
PTB1b = protein tyrosine phosphatase Ib; HIF2α = hypoxia-inducible factor 2α. 
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Figure 1: Consolidated standards of reporting trials (CONSORT) flow diagram 
 
 
Figure 2: The progression free survival of cediranib and placebo vs. cediranib 
and saracatinib 
Figure 2 legend: Kaplan-Meier analysis for PFS   
Cediranib and Saracatinib = 3.9 months (95% CI: 2.4-5.3) 
Cediranib and Placebo = 5.4 months (95% CI: 3.6-7.3)  
HR = 1.18 (95% CI: 0.94-1.48) 
 
 
 
 
Figure 3: The overall survival of cediranib and placebo vs. cediranib and 
saracatinib 
Figure 3 legend: Kaplan-Meier analysis for OS   
Cediranib and Saracatinib = 10.0 months (95% CI: 6.7-13.3) 
Cediranib and Placebo = 14.2 months (95% CI: 11.2-17.3)  
HR = 1.28 (1.00-1.63) 
 
 
Figure 4: Forest plot analysis comparing cediranib and placebo vs. cediranib 
and saracatinib for pogression free survival 
 
Figure 4 legend: Forest Plot subset analysis comparing cediranib with cediranib and 
saracatinib. The dots represent the hazard ratio value and the lines the 95% 
confidence intervals. LDH = lactate dehydrogenase; CRP = C-reactive protein; 
MSKCC = Memorial Sloan Kettering Cancer Centre risk score. 
 
 
